Rhumbline Advisers Lexicon Pharmaceuticals, Inc. Call Options Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LXRX
# of Institutions
131Shares Held
240MCall Options Held
617KPut Options Held
286K-
Artal Group S.A. Luxembourg, N4175MShares$228 Million18.64% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$12.9 Million0.0% of portfolio
-
Braidwell LP Stamford, CT8.29MShares$10.8 Million0.44% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.68MShares$9.98 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.85MShares$7.6 Million0.24% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $245M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...